Chromatography
Pluripotent Stem Cell Line Assessment qPCR Kit
Aug 05 2011
Amsbio has announced the launch of the PluriPCR™ Kit, a new benchmark to revolutionie the definition of stem cell pluripotency.
The PluriPCR kit has been designed as a quantitative, easy to use, and reliable assay of five genes strongly specific to pluripotency. These genes: Oct-3/4, Nanog, DNMT3b, Dppa4, and Rex1 are expressed by human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC); all are sharply downregulated
during differentiation.
For the first time ever stem cell scientists are now able to accurately and unambiguously define the pluripotency of a cell line using the PluriPCR Kit. Both simple and easy to use with existing real time quantitative PCR equipment. PluriPCR uses five key genes, in combination with a unique normaliation method, which gives a reliable and quantitative readout for the pluripotency of a cell line. This kit is ideally suited for all aspects of pluripotent stem cell research - measure if culture conditions are resulting in the loss of pluripotency, to assess successful nuclear reprogramming of iPS cells and even as a release assay in the manufacture and clinical development of pluripotent stem cells.
The PluriPCR kit is fully optimied for routine quality control using either two-step or one-step Real-time Quantitative PCR (qRT-PCR) methods. The assay kit combines multiple pluripotency and housekeeping markers and an analysis tool to assess the pluripotency of your cell line. The resultant PluriPCR Index is a simple method to understand if your pluripotent stem cells are differentiating.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia